Avillion Signs Co-Development Agreement with Pearl Therapeutics Inc. (part of AstraZeneca) to Conduct Clinical Development of PT027 in Asthma

March 12, 2018

Responsive image

LONDON, March 13, 2018 /PRNewswire/ —
Avillion, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval, has signed a clinical co-development agreement with Pearl Therapeutics Inc., a…

Category: Precious Metals